KALI'S POLYETHYLENE GLYCOL GETS FDA APPROVAL
Kali Laboratories' abbreviated new drug application for polyethylene glycol 3350, indicated for the treatment of occasional constipation, has been approved by the FDA. The drug is the generic equivalent of Miralax, manufactured by Braintree Laboratories.
Total annual sales of polyethylene glycol 3350 could exceed $150 million, Kali reported. The company will begin shipping the drug immediately.